CapTemY90 for Grade 2/3 NET Liver Metastases

Exclusion Criteria

• •Contraindications to capecitibine or temozolomide
• •Contraindicated for both contrast-enhanced MRI and CT
• •Patients previously treated with transarterial embolization (with or without chemotherapy) or with radioembolization (Y-90 microspheres)
• •Contraindication for radioembolization procedures:
• •excessive hepatopulmonary shunt as determined by the investigator
• •inability to deliver Y90 microspheres without risk of non-target embolization of extra-hepatic structures
• •Subjects consenting to the trial who fail their simulation angiography will be removed from the study and replaced.
• •Patients may not be receiving any other investigational agents.
• •Absolute contraindication to intravenous iodinated contrast (Hx of significant previous contrast reaction, not mitigated by appropriate pre-medication).
• •Choledochoenteric anastomosis, transpapillary stent or sphincterotomy of duodenal papilla;
• •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• •Pregnant and lactating women are ineligible